After Myriad, what makes a gene patent claim 'markedly different' from nature?
Nature Biotechnology 35, 820 (2017).
doi:10.1038/nbt.3953
Authors: Mateo Aboy, Johnathon Liddicoat, Kathleen Liddell, Matthew Jordan & Cristina Crespo
Examining the types of claim amendments that have transformed isolated gene claims from patent-ineligible into eligible subject matter provides clarity into the threshold of eligibility for gene-related patents.
Source: Nature Biotechnology - Category: Biotechnology Authors: Mateo Aboy Johnathon Liddicoat Kathleen Liddell Matthew Jordan Cristina Crespo Tags: Feature Source Type: research